264919-85-9

Basic information

• Product Name: 2-(2-(BENZYLOXY)-1-METHOXYETHYLIDENE)MALONONITRILE
• Synonyms: 2-(2-(BENZYLOXY)-1-METHOXYETHYLIDENE)MALONONITRILE
• CAS NO: 264919-85-9
• Molecular Formula: C₁₃H₁₂N₂O₂
• Molecular Weight: 228.24658
• Mol File: 264919-85-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 452.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.155±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(2-(BENZYLOXY)-1-METHOXYETHYLIDENE)MALONONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-(BENZYLOXY)-1-METHOXYETHYLIDENE)MALONONITRILE(264919-85-9)
• EPA Substance Registry System: 2-(2-(BENZYLOXY)-1-METHOXYETHYLIDENE)MALONONITRILE(264919-85-9)

Safety Data

• Hazardous Substances Data: 264919-85-9(Hazardous Substances Data)

Usage

Chemical structure

A malononitrile core with a benzyl ether moiety attached.

Versatility

A versatile building block in organic synthesis.

Common use

Employed in the preparation of various heterocyclic and polyfunctionalized compounds.

Key precursor

Serves as a key precursor in the synthesis of pharmaceuticals, agrochemicals, and functional materials.

Unique structure

The compound has a unique structure that contributes to its reactivity and importance as an intermediate.

Potential applications

Important intermediate in the development of new molecular entities with potential biological activities.

Functional groups

Contains functional groups that allow for further modification and derivatization.

Tailoring properties

Its properties can be tailored for specific applications in fields such as medicinal chemistry, materials science, and fine chemical synthesis.

Upstream product

• 264919-83-7 2-[2-(benzyloxy)-1-hydroxyethylidene]propanedinitrile 
• 19810-31-2 Benzyloxyacetyl chloride 
• 30379-55-6 benzyloxyacetic acid 
• 77-78-1 dimethyl sulfate 
• 1151653-29-0 2-(2-(benzyloxy)acetyl)malononitrile 

Downstream Products

• 1151653-30-3 5-amino-3-benzyloxymethyl-1-tert-butyl-1H-pyrazole-4-carbonitrile 

Relevant articles and documents

CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO

The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, P. falciparum, C. hominis, or C. parvum infections, using the novel inhibitors of the invention.

PYRAZOLOPYRIMIDINE PDE9 INHIBITORS

The present invention is directed to amino and alkyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such co

PYRAZOLOPYRIMIDINE PDE9 INHIBITORS

The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.